The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials
Abstract
BACKGROUND AND PURPOSE: The role of anticoagulant treatment for acute cardioembolic stroke is uncertain. We performed an updated meta-analysis of all randomized trials to obtain the best estimates of the efficacy and safety of anticoagulants for the initial treatment of acute cardioembolic stroke. METHODS: Using electronic and manual searches of the literature, we identified randomized trials comparing anticoagulants (unfractionated heparin or low-molecular-weight heparin or heparinoids), started within 48 hours, with other treatments (aspirin or placebo) in patients with acute ischemic cardioembolic stroke. Two reviewers independently selected studies and extracted data on study design, quality, and clinical outcomes, including death or disability, all strokes, recurrent ischemic stroke, and cerebral symptomatic bleeding. Odds ratios for individual outcomes were calculated for each trial and data from all the trials were pooled using the Mantel-Haenszel method. RESULTS: Seven trials, involving 4624 patients with acute cardioembolic stroke, met the criteria for inclusion. Compared with other treatments, anticoagulants were associated with a nonsignificant reduction in recurrent ischemic stroke within 7 to 14 days (3.0% versus 4.9%, odds ratio 0.68, 95% CI: 0.44 to 1.06, P=0.09, number needed to treat=53), a significant increase in symptomatic intracranial bleeding (2.5% versus 0.7%, odds ratio 2.89; 95% CI: 1.19 to 7.01, P=0.02, number needed to harm=55), and a similar rate of death or disability at final follow up (73.5% versus 73.8%, odds ratio 1.01; 95% CI: 0.82 to 1.24, P=0.9). CONCLUSIONS: Our findings indicate that in patients with acute cardioembolic stroke, early anticoagulation is associated with a nonsignificant reduction in recurrence of ischemic stroke, no substantial reduction in death and disability, and an increased intracranial bleeding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Parenteral anticoagulants seem to be associated with a non-significant reduction in recurrent ischaemic stroke when administered 7 to 14 days after the acute stroke (odds ratio [OR] 0.68; 95% CI 0.44-1.06),with a significant increase in symptomatic intracranial bleeding (OR 2.89; 95% CI 1.19-7.01),and a similar rate of death or disability at final follow-up.477”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [477]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Probability of stroke: a risk profile from the Framingham Study.
Wolf, P. A., D'Agostino, R. B., Belanger, A. J., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.3.312 · Cited by 1,782 · cited 3×
“These criteria include: (1) proper generation of the treatment allocation sequence; (2) proper concealment of the allocation sequence; (3) blinding of the patient and the investigator assessing clinical outcomes to treatment allocation; and (4) completeness of follow up.”
Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study
Wolf, P. A., Dawber, T. R., Thomas, H. E., & Kannel, W. B. (1978) · Neurology · doi:10.1212/wnl.28.10.973 · Cited by 1,526
Chen, Z.-M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04010-5 · Cited by 1,251
Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke
Albers, G. W., Bates, V. E., Clark, W. M., BELL, R. D., Verro, P., & Hamilton, S. (2000) · JAMA · doi:10.1001/jama.283.9.1145 · Cited by 697
The Publications Committee for the Trial of ORG 10172 in Acute Stroke; Treatment (TOAST) Investigators, T. P. C. F. T. T. O. O. 1. I. A. S. T. (. I. (1998) · JAMA · doi:10.1001/jama.279.16.1265 · Cited by 527
Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke
Kay, R., Wong, K. S., Yu, Y. L., Chan, Y. W., Tsoi, T. H., Ahuja, A. T., Chan, F. L., Fong, K. Y., Law, C. B., Wong, A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332402 · Cited by 472
Research works printed but not linked: 11
- 10.1161/str.22.3.2003301 · DOI
- 10.1161/str.14.5.6658950 · DOI
- Cazzato G, Zorzon M, Mase G, Antonutti L, Iona LG. Il mesoglicano nelle ischemie cerebrali acute a focolaio. Rev Neurol. 1989; 59: 121–126.
- Kwiecinski H, Pniewski J, Kaminska A, Szyluk B. A randomized trial of Fraxiparine in acute ischemic stroke [Abstract]. Cerebrovasc Dis. 1995; 5: 234.
- 10.1161/str.32.1.22 · DOI
- 10.1161/str.21.9.2396265 · DOI
- 10.1161/str.32.10.2333 · DOI
- 10.1161/str.14.5.6362091 · DOI
- 10.1161/str.33.3.856 · DOI
- 10.1161/str.30.7.1326 · DOI
- 10.1161/str.31.7.1770 · DOI
Cited by
Sorted by citations
Items 301–306 of 306
Itabashi, R., Yoshimura, S., Koga, M., Nakai, M., Wada, S., Miyamoto, Y., Matsumoto, K., Yagita, Y., Inaba, M., Katayama, M., et al. (2026) · International Journal of Stroke · doi:10.1177/17474930261427471
カツマタ, マ., Katsumata, M., & 勝又, 雅. (2019) · Institutional Repositories DataBase (IRDB)
Ahmad, M. N., Waheed, A., Gandhi, N. M., Rayamajhi, S., Alsayed, M. A., Banerjee, S., Loiola, J. D. L., Yousuf, H. M., Udo, E. A., Bista, M., et al. (2026) · Journal of Arrhythmia · doi:10.1002/joa3.70328
The efficacy and safety of antithrombotic drug options in acute ischemic stroke
Laudisi, M., Ferri, C., Pugliatti, M., & Paciaroni, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2658075
Self-citationClinical Factors which Affect the Amount and Length of Intravenous Heparin Infusion in Stroke
Choi, J. Y., & Kim, M.-W. (2009) · Journal of Korean Biological Nursing Science
Metadata
- Authors
- Paciaroni, M., Agnelli, G., Micheli, S., & Caso, V.
- Affiliations
- University of Perugia (IT)
- Venue
- Stroke
- Published
- 2007-02
- Volume
- 38
- Issue
- 2
- Pages
- 423-430
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2138775201
- Cited by
- 307
- References
- 48
- Citations by year
- 2026: 8 · 2025: 4 · 2024: 7 · 2023: 17 · 2022: 23 · 2021: 26 · 2020: 17 · 2019: 19 · 2018: 12 · 2017: 16 · 2016: 20 · 2015: 15 · 2014: 22 · 2013: 19 · 2012: 14
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Stroke (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
- Keywords
- cardioembolic stroke, anticoagulation, heparin, low molecular weight heparin, heparinoids, aspirin, recurrent ischemic stroke, intracranial hemorrhage, stroke mortality and disability
- MeSH terms
- Anticoagulants, Embolism, Humans, Randomized Controlled Trials as Topic, Myocardial Ischemia, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
